And some researchers hoped that the drugs could also help with some of the most difficult diseases to treat — those of the brain, like Parkinson’s. But now, at least for Parkinson’s ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. For their research, published in ...

A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form ... impacting mood and causing a decline in cognition. A drug that blocks a key receptor linked with ...

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds By India Edwards HealthDay Reporter WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being developed in Hamilton after a McMaster University researcher discovered a new ...

AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...

Dyskinesia hampers the quality of life for most Parkinson's disease patients following several years of therapy. However, the severity of L-Dopa-induced dyskinesia (LID) varies between patients ...